Stock DNA
Pharmaceuticals & Biotechnology
JPY 50,720 Million (Small Cap)
15.00
NA
0.00%
-0.62
-999,999.00%
2.61
Revenue and Profits:
Net Sales:
2,687 Million
(Quarterly Results - Dec 2025)
Net Profit:
1,013 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-18.74%
0%
-18.74%
6 Months
-10.27%
0%
-10.27%
1 Year
0%
0%
0.0%
2 Years
0%
0%
0.0%
3 Years
0%
0%
0.0%
4 Years
0%
0%
0.0%
5 Years
0%
0%
0.0%
Kitazato Corp. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
5.00%
EBIT Growth (5y)
6.19%
EBIT to Interest (avg)
0
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
0
Sales to Capital Employed (avg)
0
Tax Ratio
Tax Ratio is Negative%
Dividend Payout Ratio
43.29%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
15
Industry P/E
Price to Book Value
2.95
EV to EBIT
7.84
EV to EBITDA
7.61
EV to Capital Employed
6.13
EV to Sales
4.40
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
78.17%
ROE (Latest)
19.64%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
RSI
No Signal
Bollinger Bands
Mildly Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Dow Theory
Bearish
No Trend
OBV
Bearish
Bearish
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Annual Results Snapshot (Consolidated) - Mar'25
Mar'25
Mar'24
Change(%)
Net Sales
10,302.00
10,080.00
2.20%
Operating Profit (PBDIT) excl Other Income
5,959.00
6,090.00
-2.15%
Interest
1.00
1.00
Exceptional Items
-42.00
36.00
-216.67%
Consolidate Net Profit
3,788.00
3,972.00
-4.63%
Operating Profit Margin (Excl OI)
561.40%
586.60%
-2.52%
USD in Million.
Net Sales
YoY Growth in year ended Mar 2025 is 2.20% vs 7.83% in Mar 2024
Consolidated Net Profit
YoY Growth in year ended Mar 2025 is -4.63% vs 17.86% in Mar 2024






